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Summary Epidemiological studies have demonstrated a clustering of breast and prostate cancers in some families. Moreover, there is an
increase in the number of cases of prostate cancer in families with inherited mutations of the breast cancer susceptibility gene BRCA 1. We
assessed the role of BRCA1 and BRCA2 in prostate cancer. We tested for the BRCAl 185delAG frameshift mutation, found in 0.9% of
Ashkenazi Jews, and the BRCA2 6174delT mutation, found in 1% of Ashkenazi Jews, in Ashkenazi Jewish men with prostate cancer. We
studied 60 Ashkenazi men with prostate cancer. A family history was obtained by interview or a self-report questionnaire. Histological
confirmation of diagnosis was obtained for all subjects. Ethnic background was confirmed for all subjects by self-report or interview. Mutations
of BRCA 1 and BRCA2 were detected by amplification of lymphocyte DNA from peripheral blood according to standard polymerase chain
reaction (PCR) and dot blot procedures. Patients' ages ranged from 55 to 80 years (mean ± s.d. 70± 5.25). There were six men with a family
history of prostate cancer; three of these had a father with prostate cancer. Five of the men had a family history of breast cancer, in a mother,
a sister or an aunt. None,of the men had a family history of both breast and prostate cancer. None of the 60 men carried the 185delAG BRCA 1
or 6174delT BRCA2 mutations. Of 268 Ashkenazi Jewish women with sporadic breast cancer, tested in an unrelated study, 16 carried either
the 185delAG mutation of BRCA 1 or the 6174delT mutation of BRCA2. There was a significant difference in the incidence of the BRCA 1 and
BRCA2 mutations in the breast and prostate cancer cases (P = 0.05, two-tailed Fisher's exact test). The contribution of germline BRCA 1 and
BRCA2 mutations to prostate cancer incidence is probably small and could be limited to specific subgroups.
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Prostate cancer is the most common malignancy found in
American men (Boring et al, 1994). Although dietary fat plays a
role in the development of this cancer (Pienta and Esper, 1993),
and possibly also vasectomy (Giovannucci et al, 1993), family
history is one of the strongest risk factors (Whittemore et al,
1995). Indeed, there may be a gene for prostate cancer on the long
arm of chromosome 1 (Smith et al, 1997) although there is some
evidence that the breast cancer susceptibility genes BRCAJ and
BRCA2 may also be involved.
Epidemiological studies have demonstrated a clustering of
breast and prostate cancers in some families (Sellers et al, 1994).
Moreover, there is an increase in the number of cases of prostate
cancer in families with inherited mutations ofBRCA] (Ford et al,
1994; Struewing et al, 1997); loss of heterozygosity studies also
implicate BRCAI (Gao et al, 1995 a and b), which is located on the
long arm ofchromosome 17.
To assess the role of BRCAJ in prostate cancer, Langston et al
(1996a) screened for germline BRCAJ mutations in a subset of
men from an ongoing population-based case-control study of
prostate cancer. Langston et al selected a group of 49 men with
prostate cancer in whom genetic factors were most likely to be
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relevant, and found BRCAI mutations in seven (14.3%) of these
men: one known BRCA1 mutation plus six more rare sequence
variants. One mutation that Langston et al found was in a Jewish
family with multiple cases ofprostate cancer and the mutation was
185delAG.
Since BRCA1 and BRCA2 were cloned, many unique mutations
of these two genes have been detected in the germ line of individ-
uals with breast and ovarian cancer(Miki et al, 1994; Wooster et al
1994; Friedman et al, 1995). In high-risk pedigrees, female
carriers of BRCAJ mutations have an 80-90% lifetime risk of
breast cancer and a 40-50% lifetime risk of ovarian cancer (Ford
et al 1994). Following the finding ofa 185delAG frameshift muta-
tion ofBRCAJ in several Ashkenazi Jewish breast/ovarian cancer
families, the frequency of this mutation was found to be 0.9%
(Struewing et al, 1995). The 6174delT mutation of BRCA2 has a
1% incidence in Ashkenazi Jews (Oddoux et al, 1996). We studied
a group of Ashkenazi men with prostate cancer, but failed to find
the 185delAG or 6174delT mutations.
SUBJECTS AND METHODS
Participants for our study were found via urology and radiation
oncology clinics, and all eligible patients were asked to take part in
the study. A family history was obtained by interview or self-
report questionnaire. Histological confirmation of diagnosis was
obtained for all subjects. Ethnic background was confirmed for all
subjects by self-report or interview. All participants gave informed
consent for genetic studies and were not given the option to know
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their test results. Extensive genetic counselling, covering options
for detection and prevention, was available. Although we used
mostly sporadic cases ofprostate cancer, some germline mutations
would still be expected. Indeed, Langston et al (1996b) found
BRCAI germline mutations in 10% of a cohort of young women
with breast cancer, many without a family history of breast or
ovarian cancer. Fitzgerald et al (1996) also noted that these muta-
tions can be present in young women with breast cancer who do
not belong to families with multiple affected members.
Mutations of BRCA] and BRCA2 were detected by amplifica-
tion of lymphocyte DNA from peripheral blood according to stan-
dard polymerase chain reaction (PCR) and dot blot procedures
(Sambrook et al, 1989). The following primers for PCR were
added to the reaction mixture:
BRCAI prifiiers
5'> GAA GTT GTC ATT TTA TAA ACC TTT < 3' (forward)
5'> TGT CTT TTC TTC CCT AGT ATG T < 3' (reverse)
BRCA2 primers
5' > AGT TTC TAA AAT ATC ACC TTG TG <3' (forward)
5' > GTC TGA ATG TTC GTT ACT TTT AA < 5' (reverse)
Aliquots of amplified DNA were transferred to membranes
(Hybond) using a standard protocol (Sambrook et al, 1989).
Hybridization was performed for 60 min at 42°C. The following
32P-labelled probes were used for dot blot analysis:
BRCA1
5'> AAT CTT AGA GTG TCC CA 3'< (wild type)
5 ' > ATC TTA GTG TCC CAT CT 3 ' < (1 85delAG mutant)
BRCA2
5'> ACA GCA AGT GGA AAA TC 3' < (wild type)
5 ' > ACA GCA AGG GAA AAT CT 3 ' < (6174delT mutant)
Positive and negative controls were included in all runs.
RESULTS
We studied 60 Ashkenazi men with prostate cancer, ranging in age
from 55 to 80 years (mean ± s.d. 70 ± 5.25). There were six men
with a family history of prostate cancer, three of whom had a
father with prostate cancer. Five ofthe men had a family history of
breast cancer, in a mother, a sister or an aunt. None ofthe men had
a family history of both breast and prostate cancer. None of the 60
men carried the 185delAG BRCA] or 6174delT BRCA2 mutations.
Our results in prostate cancer may be compared with our results
in breast cancer. Of 268 Ashkenazi Jewish women with sporadic
breast cancer previously tested in an unrelated study, 16 carried
either the 185delAG mutation ofBRCAJ or the 6174delT mutation
of BRCA2 (Dr C. Eng, personal communication). There was a
significant difference in the incidence of the BRCAJ and BRCA2
mutations in the breast and prostate cancer cases (P = 0.05, two
tailed Fisher's exact test).
CONCLUSIONS
A recent epidemiological analysis by Isaacs et al (1995) failed to
identify a significantly increased risk ofbreast cancer among rela-
tives of prostate cancer patients. Our findings are consistent with
the findings of Isaacs et al. Furthermore, there is no evidence of
genetic linkage between BRCA1 and prostate cancer in high risk
families (Eastman, 1996; Stephenson, 1996).
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The results of our study pertain only to the 185delAG mutation
of BRCA] and the 6174delT mutation of BRCA2. Nevertheless,
the overall contribution ofgermline BRCAI and BRCA2 mutations
to prostate cancer incidence are probably small and could be
limited to specific subgroups, such as that studied by Langston et
al (1996a). Indeed, a mutation of a tumour-suppressor gene distal
to the BRCAJ locus on the long arm ofchromosome 17 may make
a much greater contribution (Williams et al, 1996). A mutation on
chromosome 1 may also play a role (Smith et al, 1997). Larger
population-based studies of tumour and normal tissue from men
with prostate cancer would be worthwhile as well as a complete
analysis ofBRCA] and BRCA2 in the subjects.
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